Cel-Sci Comments On Phase III (CVM)

CEL-SCI Corporation

announced today that it has begun its phase III clinical trial in head and neck cancer. This is big news for the company, with shares hitting a high over 30% over yesterday's close before settling into a 10%-higher trading range. Benzinga decided it was time to call the company. In its announcement today, Cel-Sci said it expects to enroll approximately 880 patients to test its leading therapy Multikine as an initial treatment for newly diagnosed head and neck cancer patients. The company says this will be the largest head and neck cancer study ever conducted. Having completed all of the manufacturing and regulatory requirements to begin enrollment of the study, the goal of this study is to establish Multikine as a first-line standard of care therapy in treating newly diagnosed head and neck cancer patients. Investors always like to see their companies trailblaze, although they also understand that trailblazing requires much more effort than cruising within another company's wake. Indeed, if Cel-Sci can complete this large study, it could have significant impact on the commercial potential of Cel-Sci's treatment product. On the phone today with Benzinga, Cel-Sci mentioned that they are extremely excited about its launch into phase III and sees definite potential for commercialization of their treatment product pending positive data from the study. They were proud to have completed the goal of phase III within their set timeline, highlighting management's ability to accurately guide the company and deliver on promises. Looking forward, the company noted that it is prepared for the full responsibilities of this large research study. Benzinga was given a timeframe of 12-18 months for receiving the full data from the study. Moreover, the company reiterated that it had met with the FDA and had agreed upon a conservative approach and protocols for this potentially landmark study. When asked if any new developments or roadblocks had come up since their last announcement, the company reassured Benzinga that nothing new had come up since their last announcement and that they were simply excited to begin work on their phase III study.